ImmuPharma (LON:IMM) Shares Up 28.8% - Should You Buy?

Key Points

• ImmuPharma's shares surged by 28.8% during trading, reaching a last traded price of GBX 13.98 ($0.19), significantly up from its previous close of GBX 10.85 ($0.15).
• The company reported a negative EPS of GBX (0.38) for the last quarter, with analysts anticipating a substantial negative earnings per share for the current year.
• ImmuPharma is focused on peptide-based therapeutics for autoimmune diseases and boasts a lead program, Lupuzor™, for treating Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price rose 28.8% during trading on Saturday . The stock traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). Approximately 44,749,293 shares changed hands during mid-day trading, an increase of 451% from the average daily volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Trading Up 25.3%

The company has a 50-day simple moving average of GBX 3.12 and a 200 day simple moving average of GBX 2.91. The company has a market cap of £87.51 million, a P/E ratio of -1,967.53 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, equities analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.